Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PSE reporting threshold erased

This article was originally published in The Tan Sheet

Executive Summary

The distribution of all amounts of pseudoephedrine and phenylpropanolamine fall under the Drug Enforcement Administration's enforcement, according to a final rule published July 7 in the Federal Register. The rule, which takes effect Aug. 6, is the latest step in DEA's implementation of the Combat Methamphetamine Epidemic Act. It eliminates the current threshold of 2.2 pounds to trigger DEA's reporting and recordkeeping requirements, according to a July 7 Federal Register notice. DEA says the unregulated distribution of any amount of PSE increases the likelihood the substance could be diverted to use for illicit meth manufacturing. DEA also imposed retail sales limits and tracking requirements under provisions of Combat Meth (1"The Tan Sheet" Nov. 26, 2007)

You may also be interested in...

Distributions Of All Amounts Of PSE Would Be Regulated Under DEA Rule

The Drug Enforcement Administration continues developing enforcement tools to implement the Combat Meth Act with a Nov. 20 notice of proposed rulemaking to regulate the distribution of all amounts of pseudoephedrine and phenylpropanolamine

Germany's OTC Market in 2019: Stagnation Overall, Online Growth Continues

A weak cough and cold season in Germany last winter held back OTC sales growth in 2019, according to IQVIA, while the country's online pharmacy channel continued to expand. 

Stockwatch: Choppy Waters For Teva And Bausch

After most of the big pharmaceutical companies reported their full-year 2019 financial results, the second month of earnings season brings the long tail of smaller biotech companies and the generic pharmaceutical companies. There is more than one uncomfortable parallel from the former in the reports of the latter.







Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts